Reproductive Health

News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.

Natera has entered the oncology space with a ctDNA assay and sees its blood banking service as a way to eventually tap into the consumer genomics space. 

Natera ran 17 percent more tests in Q2 than it did in the prior-year period, generating $53.6 million in total revenues.

Invitae is interested in companies that can contribute positively to its revenues in the next two to three quarters, according to CEO Sean George. 

The acquisitions will enable Invitae to add reproductive health genetic testing to its portfolio and become what it calls a "comprehensive genomic information company." 

In a revised medical policy, Aetna said it would continue to cover NIPT for high-risk pregnancies, but not average-risk ones.